ChromoTek MSLN VHH, recombinant binding protein for 2x Cys conjugation

Alpaca anti-MSLN VHH, purified recombinant binding protein. Suitable for for cysteine conjugation with thiol-reactive reagents, e.g. maleimides. Note: unconjugated VHHs are not suited for usage without prior labeling, since they contain reactive Cysteines. Shipment and storage buffers contain TCEP to keep Cysteins reduced.
Cat No. mslnCys2

Host/Type

Alpaca VHH

Reactivity

Human

Applications

Conjugation

Conjugate

Unconjugated

MSLN-Nanobody, MSLN-Single domain antibody (sdAb), CAK1 antigen, pre-pro-megakaryocyte-potentiating factor, MPF, MSLN, Mesothelin

SKU/Size: 

-/ -

Freight/Packing: -

Quantity

Please visit your regions distributor:


Product Information

Alpaca anti-MSLN VHH, purified recombinant binding protein. Suitable for for cysteine conjugation with thiol-reactive reagents, e.g. maleimides. Note: unconjugated VHHs are not suited for usage without prior labeling, since they contain reactive Cysteines. Shipment and storage buffers contain TCEP to keep Cysteins reduced.

ApplicationsConjugation
ReactivityHuman
ConjugateUnconjugated
TypeNanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight15.710 kDa
FormLiquid
RRIDAB_3101940
Storage Buffer10 mM HEPES, 500 mM NaCl, pH 7.0, 1 mM TCEP, 0.09% sodium azide
Storage ConditionStore at -20°C
BackgroundMesothelin (MSLN) is a 40kDa GPI-anchored surface glycoprotein that is expressed on pleural and peritoneal mesothelial cells, but not in other non-neoplastic tissues. The mesothelin gene encodes a 69-71kDa precursor protein that is processed to a 40kDa membrane-bound protein termed mesothelin and a 31kDa shed fragment called megakaryocyte-potentiating factor (MPF) that is released from the cell. Mesothelin is a tumor differentiation antigen present at low levels on a restricted set of normal adult tissues (e.g. mesothelium), and is expressed at high levels in mesotheliomas, as well as ovarian, pancreatic, and lung cancers. Mesothelin may be a new target for immunotherapy (PMID: 20922056, 18691948, 15217923).